Evommune (EVMN) FCF Margin (2025)
Evommune (EVMN) reported FCF Margin of 796.63% for Q1 2025.
Evommune (EVMN) has 1 years of FCF Margin data on file, last reported at 796.63% in Q1 2025.
- Quarterly FCF Margin changed N/A year-over-year to 796.63% in Q1 2025, while the trailing twelve-month figure through Mar 2026 was 523.75% (changed N/A YoY) and the FY2025 annual result came in at 588.28%, up 24434.0% from the prior year.
- FCF Margin held at 796.63% in Q1 2025 per EVMN's latest filing.
- Across five years, FCF Margin topped out at 796.63% in Q1 2025 and bottomed at 796.63% in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -3.98% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 43.35% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 23.53% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 4.17% |
| 10 | Evommune | 782.16 Mn | 570.69 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -796.63% |